This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2000;283:596.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved aminolevulinic acid HCl (ALA HCl) (Levulan Kerastick for topical solution, 20%, DUSA Pharmaceuticals Inc, Valhalla, NY) to be used with photodynamic therapy for the treatment of actinic keratoses (AKs) of the face or scalp. It is the first combined drug and device designed for targeted treatment that can be limited to the lesion site(s).

Levulan Kerastick consists of a plastic tube with an applicator and two sealed glass ampules, one containing an alcohol-based solution vehicle and the other containing 354 mg of ALA HCl as a dry solid. The topical solution is prepared just prior to its use by breaking the ampules and shaking the applicator to mix the contents. The solution is applied by a physician directly to the AK lesions, and 14 to 18 hours later is photoactivated with the Blu-U Blue Light photodynamic therapy illuminator, a special radiation source designed to provide a . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?